Search Results

Key points Olutasidenib induces durable responses in patients with relapsed or refractory (R/R) acute myeloid leukaemia (AML) with isocitrate dehydrogenase 1 (IDH1) mutations in the phase I and II clinical trials. The side effects of olutasidenib are well known and highly manageable. Olutasidenib represents a therapeutic advance for these patients with a poor prognosis. Olutasidenib received the […]

The management of children with diffuse midline gliomas (DMG) and other paediatric high-grade gliomas (pHGG) continue to present one of the most difficult challenges facing paediatric oncologists, characterized by poor patient outcomes.1 Standard of care therapy, which includes a maximal safe resection where possible, followed by focal radiation therapy, has remained unchanged for decades. This therapy, […]

Adult-type diffuse low-glade gliomas (LGGs) (World Health Organization [WHO] grade 2) represent 5–10% of all primary brain tumours.1 The median age of onset is in the third and fourth decades of life. Common clinical presentations include seizures, focal neurological deficits, and new-onset headaches.2 Magnetic resonance imaging (MRI) demonstrates T1 signal hypointensity and T2/fluid attenuated inversion recovery (FLAIR) hyperintensity […]

Advanced non-small cell lung carcinoma (NSCLC) treatment paradigms have evolved during the past decade. Identification of tumor-specific molecular alteration in cancer driver genes has led to the development of targeted therapies.1–3 Most of the tumors harboring such alterations are sensitive to tyrosine kinase inhibitor (TKI) drugs, making such oncogenic drivers promising targets for the development of […]

Welcome to the summer edition of European Oncology & Haematology. The COVID-19 pandemic has had a devastating impact on cancer and other illness care. In addition to the heightened susceptibility of patients with cancer to infections, lockdown has resulted in delayed screening and reduced treatment of early-stage disease. However, things are starting to move in the […]

Pancreatic ductal adenocarcinoma (PDA) is predicted to beat colon cancer in terms of total cancer-related deaths in the USA by this year (2020).1 Given this projected burden of disease, efforts in understanding and developing new treatments for PDA are paramount. In this review, we will summarize the molecular characteristics and mutations thought to be involved with […]

Regorafenib was approved as a third-line treatment for colorectal cancer in 2013. Notwithstanding its promising pharmacodynamics, 5 years after its introduction, only a small subgroup of patients has profited from this drug, and in those who did, the treatment effects were surprisingly restricted.1 Regorafenib is an oral multikinase inhibitor against vascular endothelial growth factor receptor […]

Therapeutic cancer vaccination is a promising strategy that aims to treat late stage disease by using the patient’s own immune system.1 The immune system has the potential to eliminate cancer cells, since cancer cells express antigens that are unique to the tumour or are over-expressed in the tumour. However, despite many years of research, the effective […]

Introduction Presented by Sean Bohen Oncology is one of the cornerstone therapeutic areas for AstraZeneca, and within the AstraZeneca oncology drug discovery platform there are four main research areas: tumour drivers and resistance, immuno-oncology, antibody conjugates and the DNA damage response (DDR). The pursuit of oncology drugs targeted at the DDR is based on tumour […]